MedTrace Logo

Hydroxychloroquine in Primary Progressive Multiple Sclerosis

NCT02913157 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 35

Last updated 2021-07-30

No results posted yet for this study

Summary

The purpose of this clinical trial is to determine if HCQ in a dose of 400mg daily can prevent worsening of walking ability in people PPMS. The number of participants in this study will be 35. A maximum of 42 people with PPMS will be included. The trial is funded through a private donation to the Hotchkiss Brain Institute MS Translational Clinical Trials Research Program and the University of Calgary. There is no sponsorship from the pharmaceutical industry.

Conditions

  • Multiple Sclerosis, Primary Progressive

Interventions

DRUG

Hydroxychloroquine

Orally administered Hydroxychloroquine

Sponsors & Collaborators

  • University of Calgary

    lead OTHER

Principal Investigators

  • Marcus Koch · University of Calgary

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-11-30
Primary Completion
2021-06-30
Completion
2021-06-30

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02913157 on ClinicalTrials.gov